interferon induced protein with tetratricopeptide repeats 6, pseudogeneGenealiases: []
Q-omics provides the consensus-scored IFIT6P profile across patient tissues and cancer cell-line models. IFIT6P expression is associated with patient survival in 13 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, IFIT6P is differentially expressed in 1, with the highest sampling consensus in KIRC. Additionally, IFIT6P RNA expression shows 6,657 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight ACC, KIRC, and STAD as cancer lineages where IFIT6P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for IFIT6P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes IFIT6P survival associations across molecular data types. IFIT6P RNA expression shows survival associations in the most cancer types (13). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible IFIT6P RNA expression–survival associations across cancer types. High IFIT6P expression shows unfavorable associations in ACC, UVM, THYM and THCA, but favorable associations in LUSC and MESO. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify ACC as the clearest survival context for IFIT6P RNA expression.
This table summarizes IFIT6P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for IFIT6P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. IFIT6P shows higher tumor expression in KIRC. The KIRC box plot shows higher IFIT6P RNA expression in tumor versus normal tissue (log2 FC = +0.042, t-test p < 0.001).
This table shows molecular features associated with IFIT6P in patient tissues and cancer cell lines. In patient samples, IFIT6P shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
